Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Sales of the drug, which comprised nearly half of Merck’s sales last year, totaling $29.5 billion, are expected to peak ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...

Adagene, Inc. (($ADAG)) announced an update on their ongoing clinical study. Study Overview: Adagene, Inc. (ADAG) is conducting a Phase 1b/2 ...

Bristol-Myers Squibb Company has had a recent 30% stock decline amid concerns over patent expirations. Click here to read why BMY stock is a Hold.

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Study Overview: Akeso, Inc. is conducting a Phase I/II study titled ...

The first-in-class FGFR2b antibody bemarituzumab extends overall survival in patients with advanced gastric cancer, but the ...

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in significant progression-free survival improvements, it fell short of the ...

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...